within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF05_Atezolizumab;

model Atezolizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.555555555555556e-08,
    adminDuration = 600,
    adminMass = 1200 / 1000000,
    adminCount = 1,
    Vd = 0.00691,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00368,
    k12 = 7.722222222222223e-08,
    k21 = 7.722222222222223e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Atezolizumab</td></tr><tr><td>ATC code:</td><td>L01FF05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.91</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Atezolizumab is a humanized monoclonal antibody of the IgG1 isotype that selectively binds to programmed death-ligand 1 (PD-L1). It is used in cancer immunotherapy for several malignancies including non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer, and more. It is FDA- and EMA-approved for several cancer indications and continues to be used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in cancer patients (adults) across clinical trials (n > 800), both sexes, mostly with advanced solid tumors (including NSCLC, urothelial carcinoma).</p><h4>References</h4><ol><li><p>Shemesh, CS, et al., &amp; Girish, S (2019). Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. <i>Journal for immunotherapy of cancer</i> 7(1) 314–None. DOI:<a href=\"https://doi.org/10.1186/s40425-019-0791-x\">10.1186/s40425-019-0791-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31753029/\">https://pubmed.ncbi.nlm.nih.gov/31753029</a></p></li><li><p>Felip, E, et al., &amp; Restuccia, E (2021). Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinical pharmacology in drug development</i> 10(10) 1142–1155. DOI:<a href=\"https://doi.org/10.1002/cpdd.936\">10.1002/cpdd.936</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33788415/\">https://pubmed.ncbi.nlm.nih.gov/33788415</a></p></li><li><p>Shemesh, CS, et al., &amp; Bruno, R (2020). Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. <i>Pharmacology research &amp; perspectives</i> 8(6) e00685–None. DOI:<a href=\"https://doi.org/10.1002/prp2.685\">10.1002/prp2.685</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33241650/\">https://pubmed.ncbi.nlm.nih.gov/33241650</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01FF05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Atezolizumab;
